UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for HIV in the United Kingdom. Explore treatment pathways including antiretroviral therapy, long-acting injectables, and cure research.
~107,000 people live with HIV in the UK, with ~5,000 new diagnoses per year (declining thanks to PrEP). Modern antiretroviral therapy (ART) means people with HIV can live long, healthy lives with a near-normal life expectancy. U=U (undetectable = untransmittable) means someone on effective ART cannot pass HIV to sexual partners. The UK aims to end new HIV transmissions by 2030.
Standard ART: daily tablet combining 2-3 drugs. Common regimens: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Dovato (dolutegravir/lamivudine). Long-acting injectable ART: cabotegravir/rilpivirine (Vocabria/Rekambys) given every 2 months - now available on NHS. Two-drug regimens reduce long-term toxicity. Treatment is lifelong; adherence is critical for maintaining viral suppression.
Pre-exposure prophylaxis (PrEP) is available free on the NHS through sexual health clinics. Daily or event-driven PrEP (emtricitabine/tenofovir) reduces HIV acquisition risk by ~99% when taken as directed. Long-acting injectable PrEP (cabotegravir, given every 2 months) is in late-stage trials. The NHS PrEP programme has been instrumental in reducing new HIV diagnoses.
Active UK HIV trials include: broadly neutralising antibodies (bNAbs) for treatment and prevention, long-acting ART (6-monthly or annual dosing), HIV cure research ("kick and kill" strategies, CRISPR gene editing), therapeutic vaccines, ART simplification strategies, and strategies to address HIV-associated comorbidities (cardiovascular disease, neurocognitive impairment). The UK's BHIVA and CHERUB collaboration drive research.
Free AI-powered matching - no signup required
Search human immunodeficiency virus Trials →